1887

Chapter 3 : Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819453/9781555819446_Chap03-1.gif /docserver/preview/fulltext/10.1128/9781555819453/9781555819446_Chap03-2.gif

Abstract:

In mid-1976 an outbreak of hemorrhagic fever was reported in southern Sudan and northern Zaire. Patients with the disease, which appeared first in southern Sudan in June 1976, presented with influenza-like symptoms including headache, fever, and myalgias and rapidly progressed to a more severe illness characterized by diarrhea, vomiting, chest pains, and hemorrhage. The disease was associated with a high mortality rate and was transmitted between close contacts of the severely ill, resulting in a substantial number of cases being linked to a local hospital ( ). An outbreak of a disease with similar symptoms was noted in northern Zaire beginning in September 1976, and by 24 October there were 280 deaths out of a total of 318 cases, for a case fatality rate of 88% ( ). When samples derived from patients affected by the Sudan and Zaire outbreaks were used to infect Vero cells in culture, guinea pigs, or mice, a filamentous virus similar to Marburg virus was observed ( ). Virus particles with a similar morphology were also identified in postmortem liver samples from patients in Zaire ( ). Antigenic comparisons of the new virus isolates and Marburg demonstrated that while there was cross-reactivity between the Sudan and Zaire viruses, they were distinct from Marburg virus, and the new isolates were designated “Ebola virus” (EBOV) after a river near the outbreak site in Zaire ( ). Unlike Marburg virus, for which a single species has been described, at least five different species of the genus exist ( ). and are the species most frequently associated with human disease ( ).

Citation: Fisher R, Borio L. 2016. Ebola Virus Disease: Therapeutic and Potential Preventative Opportunities, p 53-71. In Scheld W, Hughes J, Whitley R (ed), Emerging infections 10. ASM Press, Washington, DC. doi: 10.1128/microbiolspec.EI10-0014-2016
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555819453.chap3
1. World Health Organization . 1978. Ebola haemorrhagic fever in Sudan, 1976. Bull World Health Organ 56 : 247270.[PubMed]
2. World Health Organization . 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56 : 271293.[PubMed]
3. Bowen ET,, Lloyd G,, Harris WJ,, Platt GS,, Baskerville A,, Vella EE . 1977. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1 : 571573.[PubMed] [CrossRef]
4. Pattyn S,, van der Groen G,, Jacob W,, Piot P,, Courteille G . 1977. Isolation of Marburg-like virus from a case of haemorrhagic fever in Zaire. Lancet 1 : 573574.[PubMed] [CrossRef]
5. Johnson KM,, Lange JV,, Webb PA,, Murphy FA . 1977. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet 1 : 569571.[PubMed] [CrossRef]
6. Bukreyev AA,, Chandran K,, Dolnik O,, Dye JM,, Ebihara H,, Leroy EM,, Mühlberger E,, Netesov SV,, Patterson JL,, Paweska JT,, Saphire EO,, Smither SJ,, Takada A,, Towner JS,, Volchkov VE,, Warren TK,, Kuhn JH . 2014. Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol 159 : 821830.[PubMed] [CrossRef]
7. Weyer J,, Grobbelaar A,, Blumberg L . 2015. Ebola virus disease: history, epidemiology and outbreaks. Curr Infect Dis Rep 17 : 480. [PubMed] [CrossRef]
8. Centers for Disease Control and Prevention . 2016. Outbreaks Chronology: Ebola Virus Disease . http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html#one.
9. Khan AS,, Tshioko FK,, Heymann DL,, Le Guenno B,, Nabeth P,, Kerstiëns B,, Fleerackers Y,, Kilmarx PH,, Rodier GR,, Nkuku O,, Rollin PE,, Sanchez A,, Zaki SR,, Swanepoel R,, Tomori O,, Nichol ST,, Peters CJ,, Muyembe-Tamfum JJ,, Ksiazek TG . 1999. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J Infect Dis 179(Suppl 1): S76S86.[PubMed] [CrossRef]
10. Centers for Disease Control and Prevention (CDC) . 2001. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep 50 : 7377.[PubMed]
11. Leroy EM,, Epelboin A,, Mondonge V,, Pourrut X,, Gonzalez J-P,, Muyembe-Tamfum J-J,, Formenty P . 2009. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9 : 723728.[PubMed] [CrossRef]
12. Sanchez A,, Kiley MP,, Holloway BP,, Auperin DD . 1993. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29 : 215240.[PubMed] [CrossRef]
13. Elliott LH,, Kiley MP,, McCormick JB . 1985. Descriptive analysis of Ebola virus proteins. Virology 147 : 169176.[PubMed] [CrossRef]
14. Sanchez A,, Trappier SG,, Mahy BW,, Peters CJ,, Nichol ST . 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci USA 93 : 36023607.[PubMed] [CrossRef]
15. de La Vega M-A,, Wong G,, Kobinger GP,, Qiu X . The multiple roles of sGP in Ebola pathogenesis. Viral Immunol [Epub ahead of print.] doi:10.1089/vim.2014.0068. [PubMed] [CrossRef]
16. Ramanan P,, Shabman RS,, Brown CS,, Amarasinghe GK,, Basler CF,, Leung DW . 2011. Filoviral immune evasion mechanisms. Viruses 3 : 16341649.[PubMed] [CrossRef]
17. Berman M,, du Lac JF,, Izadi E,, Dennis B . 2014. As Ebola confirmed in U.S., CDC vows: ‘We’re stopping it in its tracks’. The Washington Post. https://www.washingtonpost.com/news/to-your-health/wp/2014/09/30/cdc-confirms-first-case-of-ebola-in-the-u-s/.
18. World Health Organization . 2016. Ebola data and statistics. http://apps.who.int/gho/data/view.ebola-sitrep.ebola-summary-latest?lang=en.
19. Butler D . 2014. Global Ebola response kicks into gear at last. Nature 513 : 469469.[PubMed] [CrossRef]
20. Meltzer MI,, Atkins CY,, Santibanez S,, Knust B,, Petersen BW,, Ervin ED,, Nichol ST,, Damon IK,, Washington ML , Centers for Disease Control and Prevention (CDC) . 2014. Estimating the future number of cases in the Ebola epidemic: Liberia and Sierra Leone, 2014-2015. MMWR Surveill Summ 63(Suppl 3): 114.
21. WHO Ebola Response Team . 2014. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med 371 : 14811495.[PubMed] [CrossRef]
22. Borio L,, Cox E,, Lurie N . 2015. Combating emerging threats: accelerating the availability of medical therapies. N Engl J Med 373 : 993995.[PubMed] [CrossRef]
23. Joffe S . 2014. Evaluating novel therapies during the Ebola epidemic. JAMA 312 : 12991300.[PubMed] [CrossRef]
24. van Griensven J,, Weiggheleire AD,, Delamou A,, Smith PG,, Edwards T,, Vandekerckhove P,, Bah EI,, Colebunders R,, Herve I,, Lazaygues C,, Haba N,, Lynen L . 2015. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin Infect Dis 62 : 6974.[PubMed] [CrossRef]
25. Gulland A . 2014. Clinical trials of Ebola therapies to begin in December. BMJ 349 : g6827. [PubMed] [CrossRef]
26. FDA . 2014. Information for consumers (drugs): the FDA’s drug review process: ensuring drugs are safe and effective. http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm.
27. Chertow DS,, Kleine C,, Edwards JK,, Scaini R,, Giuliani R,, Sprecher A . 2014. Ebola virus disease in West Africa: clinical manifestations and management. N Engl J Med 371 : 20542057.[PubMed] [CrossRef]
28. Boyles T . 2015. Priorities in Ebola research: a view from the field. Lancet 385 : 23. [PubMed] [CrossRef]
29. World Health Organization . 2014. WHO list of essential medicines necessary to treat Ebola cases. http://www.who.int/csr/resources/publications/ebola/ebola-medicines/en/.
30. Lamontagne F,, Clément C,, Fletcher T,, Jacob ST,, Fischer WA II,, Fowler RA . 2014. Doing today’s work superbly well: treating Ebola with current tools. N Engl J Med 371 : 15651566.[PubMed] [CrossRef]
31. Fowler RA,, Fletcher T,, Fischer WA II,, Lamontagne F,, Jacob S,, Brett-Major D,, Lawler JV,, Jacquerioz FA,, Houlihan C,, O’Dempsey T,, Ferri M,, Adachi T,, Lamah M-C,, Bah EI,, Mayet T,, Schieffelin J,, McLellan SL,, Senga M,, Kato Y,, Clement C,, Mardel S,, Vallenas Bejar De Villar RC,, Shindo N,, Bausch D . 2014. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am J Respir Crit Care Med 190 : 733737.[PubMed] [CrossRef]
32. Wong KK,, Perdue CL,, Malia J,, Kenney JL,, Peng S,, Gwathney JK,, Raczniak GA , Monrovia Medical Unit . 2015. Supportive care of the first 2 Ebola virus disease patients at the Monrovia Medical Unit. Clin Infect Dis 61 : e47e51.[PubMed] [CrossRef]
33. Johnson DW,, Sullivan JN,, Piquette CA,, Hewlett AL,, Bailey KL,, Smith PW,, Kalil AC,, Lisco SJ . 2015. Lessons learned: critical care management of patients with Ebola in the United States. Crit Care Med 43 : 11571164.[PubMed] [CrossRef]
34. Rodríguez-Caravaca G,, Timermans R,, Parra-Ramírez JM,, Domínguez-Hernández FJ,, Algora-Weber A,, Delgado-Iribarren A,, Hermida-Gutiérrez G , Ebola Virus Management Committee . 2015. Health-care management of an unexpected case of Ebola virus disease at the Alcorcón Foundation University Teaching Hospital. Enferm Infecc Microbiol Clin 33 : 228232.[PubMed] [CrossRef]
35. Lyon GM,, Mehta AK,, Varkey JB,, Brantly K,, Plyler L,, McElroy AK,, Kraft CS,, Towner JS,, Spiropoulou C,, Ströher U,, Uyeki TM,, Ribner BS , Emory Serious Communicable Diseases Unit . 2014. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371 : 24022409.[PubMed] [CrossRef]
36. Büttner S,, Koch B,, Dolnik O,, Eickmann M,, Freiwald T,, Rudolf S,, Engel J,, Becker S,, Ronco C,, Geiger H . 2014. Extracorporeal virus elimination for the treatment of severe Ebola virus disease: first experience with lectin affinity plasmapheresis. Blood Purif 38 : 286291.[PubMed]
37. Mora-Rillo M,, Arsuaga M,, Ramírez-Olivencia G,, de la Calle F,, Borobia AM,, Sánchez-Seco P,, Lago M,, Figueira JC,, Fernández-Puntero B,, Viejo A,, Negredo A,, Nuñez C,, Flores E,, Carcas AJ,, Jiménez-Yuste V,, Lasala F,, García-de-Lorenzo A,, Arnalich F,, Arribas JR,, La Paz-Carlos III , University Hospital Isolation Unit . 2015. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 3 : 554562.[CrossRef]
38. World Health Organization . 2014. Ethical considerations for use of unregistered interventions for Ebola virus disease. http://www.who.int/csr/resources/publications/ebola/ethical-considerations/en/.
39. Food and Drug Administration . 2016. Expanded access (compassionate use). http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm.
40. Wilson JA,, Hevey M,, Bakken R,, Guest S,, Bray M,, Schmaljohn AL,, Hart MK . 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 : 16641666.[PubMed] [CrossRef]
41. Zeitlin L,, Pettitt J,, Scully C,, Bohorova N,, Kim D,, Pauly M,, Hiatt A,, Ngo L,, Steinkellner H,, Whaley KJ,, Olinger GG . 2011. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA 108 : 2069020694.[PubMed] [CrossRef]
42. Qiu X,, Fernando L,, Melito PL,, Audet J,, Feldmann H,, Kobinger G,, Alimonti JB,, Jones SM . 2012. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 6 : e1575. doi:10.1371/journal.pntd.0001575. [PubMed] [CrossRef]
43. Pettitt J,, Zeitlin L,, Kim DH,, Working C,, Johnson JC,, Bohorov O,, Bratcher B,, Hiatt E,, Hume SD,, Johnson AK,, Morton J,, Pauly MH,, Whaley KJ,, Ingram MF,, Zovanyi A,, Heinrich M,, Piper A,, Zelko J,, Olinger GG . 2013. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 5 : 199ra113. [PubMed] [CrossRef]
44. Qiu X,, Audet J,, Wong G,, Pillet S,, Bello A,, Cabral T,, Strong JE,, Plummer F,, Corbett CR,, Alimonti JB,, Kobinger GP . 2012. Successful treatment of Ebola virus–infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4 : 138ra81. [PubMed] [CrossRef]
45. Qiu X,, Wong G,, Audet J,, Bello A,, Fernando L,, Alimonti JB,, Fausther-Bovendo H,, Wei H,, Aviles J,, Hiatt E,, Johnson A,, Morton J,, Swope K,, Bohorov O,, Bohorova N,, Goodman C,, Kim D,, Pauly MH,, Velasco J,, Pettitt J,, Olinger GG,, Whaley K,, Xu B,, Strong JE,, Zeitlin L,, Kobinger GP . 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 : 4753.[PubMed] [CrossRef]
46. McCarthyM . 2014. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ 349 : g5488. [PubMed] [CrossRef]
47. Anonymous . 2015. Putative investigational therapeutics in the treatment of patients with known Ebola infection. https://clinicaltrials.gov/ct2/show/NCT02363322.
48. National Institute of Allergy and Infectious Diseases . 2015. Liberia-U.S. clinical research partnership opens trial to test Ebola treatments. http://www.niaid.nih.gov/news/newsreleases/2015/Pages/ZMapp.aspx.
49. Whaley KJ,, Hiatt A,, Zeitlin L . 2011. Emerging antibody products and Nicotiana manufacturing. Hum Vaccin 7 : 349356.[PubMed] [CrossRef]
50. Bernstein L,, Dennis B . 2014. Ebola test drug’s supply “exhausted” after shipments to Africa, U.S. company says. The Washington Post. https://www.washingtonpost.com/national/health-science/ebola-test-drugs-supply-exhausted-after-shipments-to-africa-us-company-says/2014/08/11/020cefc0-2199-11e4-958c-268a320a60ce_story.html.
51. Pollack A . 2014. U.S. will increase production of the Ebola drug ZMapp, but may not meet demand. NY Times. http://www.nytimes.com/2014/10/02/world/us-to-increase-production-of-experimental-drug-but-may-not-meet-demand.html.
52. Fink S . 2015. A Chinese Ebola drug raises hopes, and rancor. NY Times. http://www.nytimes.com/2015/06/12/world/chinese-ebola-drug-brings-american-objections.html.
53. Sky News . 2015. Is MIL-77 the new Ebola-fighting wonder drug? Sky News. http://news.sky.com/story/1454079/is-mil-77-the-new-ebola-fighting-wonder-drug.
54. World Health Organization . 2015. Ebola vaccines, therapies, and diagnostics. http://www.who.int/medicines/emp_ebola_q_as/en/.
55. World Health Organization . 2014. Use of Convalescent Whole Blood or Plasma Collected from Patients Recovered from Ebola Virus Disease. WHO, Geneva, Switzerland. http://www.who.int/csr/resources/publications/ebola/convalescent-treatment/en/.
56. Jahrling PB,, Geisbert JB,, Swearengen JR,, Larsen T,, Geisbert TW . 2007. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis 196(Suppl 2): S400S403.[PubMed] [CrossRef]
57. Emond RT,, Evans B,, Bowen ET,, Lloyd G . 1977. A case of Ebola virus infection. BMJ 2 : 541544.[PubMed] [CrossRef]
58. Mupapa K,, Massamba M,, Kibadi K,, Kuvula K,, Bwaka A,, Kipasa M,, Colebunders R,, Muyembe-Tamfum JJ , International Scientific and Technical Committee . 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(Suppl 1): S18S23.[PubMed] [CrossRef]
59. Sadek RF,, Khan AS,, Stevens G,, Peters CJ,, Ksiazek TG . 1999. Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival. J Infect Dis 179(Suppl 1): S24S27.[PubMed] [CrossRef]
60. Jahrling PB,, Geisbert J,, Swearengen JR,, Jaax GP,, Lewis T,, Huggins JW,, Schmidt JJ,, LeDuc JW,, Peters CJ . 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 11 : 135140.[PubMed] [CrossRef]
61. Oswald WB,, Geisbert TW,, Davis KJ,, Geisbert JB,, Sullivan NJ,, Jahrling PB,, Parren PW,, Burton DR . 2007. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3 : e9. [PubMed] [CrossRef]
62. Wong G,, Richardson JS,, Pillet S,, Patel A,, Qiu X,, Alimonti J,, Hogan J,, Zhang Y,, Takada A,, Feldmann H,, Kobinger GP . 2012. Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates. Sci Transl Med 4 : 158ra146. [PubMed] [CrossRef]
63. Olinger GG,, Pettitt J,, Kim D,, Working C,, Bohorov O,, Bratcher B,, Hiatt E,, Hume SD,, Johnson AK,, Morton J,, Pauly M,, Whaley KJ,, Lear CM,, Biggins JE,, Scully C,, Hensley L,, Zeitlin L . 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 109 : 1803018035.[PubMed] [CrossRef]
64. van Griensven J,, Edwards T,, de Lamballerie X,, Semple MG,, Gallian P,, Baize S,, Horby PW,, Raoul H,, Magassouba N,, Antierens A,, Lomas C,, Faye O,, Sall AA,, Fransen K,, Buyze J,, Ravinetto R,, Tiberghien P,, Claeys Y,, De Crop M,, Lynen L,, Bah EI,, Smith PG,, Delamou A,, De Weggheleire A,, Haba N , Ebola-Tx Consortium . 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374 : 3342.[PubMed] [CrossRef]
65. Florescu DF,, Kalil AC,, Hewlett AL,, Schuh AJ,, Stroher U,, Uyeki TM,, Smith PW . 2015. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin Infect Dis 61 : 969973.[PubMed] [CrossRef]
66. Kraft CS,, Hewlett AL,, Koepsell S,, Winkler AM,, Kratochvil CJ,, Larson L,, Varkey JB,, Mehta AK,, Lyon GM,, Friedman-Moraco RJ,, Marconi VC,, Hill CE,, Sullivan JN,, Johnson DW,, Lisco SJ,, Mulligan MJ,, Uyeki TM,, McElroy AK,, Sealy T,, Campbell S,, Spiropoulou C,, Ströher U,, Crozier I,, Sacra R,, Connor MJ,, Sueblinvong V,, Franch HA,, Smith PW,, Ribner BS . 2015. Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin Infect Dis 61 : 496502.[PubMed] [CrossRef]
67. Liddell AM,, Davey RT Jr,, Mehta AK,, Varkey JB,, Kraft CS,, Tseggay GK,, Badidi O,, Faust AC,, Brown KV,, Suffredini AF,, Barrett K,, Wolcott MJ,, Marconi VC,, Lyon GM III,, Weinstein GL,, Weinmeister K,, Sutton S,, Hazbun M,, Albariño CG,, Reed Z,, Cannon D,, Ströher U,, Feldman M,, Ribner BS,, Lane HC,, Fauci AS,, Uyeki TM . 2015. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 163 : 8190.[PubMed] [CrossRef]
68. U.S. Securities and Exchange Commission . 2010. Biopharma AVI. 10-Q report. http://www.sec.gov/Archives/edgar/data/873303/000110465910043138/a10-12966_110q.htm.
69. Zamecnik PC,, Stephenson ML . 1978. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75 : 280284.[PubMed] [CrossRef]
70. Watts JK,, Corey DR . 2012. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. J Pathol 226 : 365379.[PubMed] [CrossRef]
71. Warfield KL,, Swenson DL,, Olinger GG,, Nichols DK,, Pratt WD,, Blouch R,, Stein DA,, Aman MJ,, Iversen PL,, Bavari S . 2006. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2 : e1. doi:10.1371/journal.ppat.0020001. [PubMed]
72. Warren TK,, Warfield KL,, Wells J,, Swenson DL,, Donner KS,, Van Tongeren SA,, Garza NL,, Dong L,, Mourich DV,, Crumley S,, Nichols DK,, Iversen PL,, Bavari S . 2010. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 16 : 991994.[PubMed] [CrossRef]
73. Heald AE,, Iversen PL,, Saoud JB,, Sazani P,, Charleston JS,, Axtelle T,, Wong M,, Smith WB,, Vutikullird A,, Kaye E . 2014. Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies. Antimicrob Agents Chemother 58 : 66396647.[PubMed] [CrossRef]
74. Warren TK,, Whitehouse CA,, Wells J,, Welch L,, Heald AE,, Charleston JS,, Sazani P,, Reid SP,, Iversen PL,, Bavari S . 2015. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. mBio 6 : e02344-14. doi:10.1128/mBio.02344-14. [PubMed] [CrossRef]
75. U.S. Securities and Exchange Commission . 2015. Sarepta Therapeutics, Inc. 10-Q Report. http://www.sec.gov/Archives/edgar/data/873303/000156459015009495/srpt-10q_20150930.htm.
76. Calma J . 2015. Ebola drug killed by congressional inaction less than two years before outbreak. NOVA Next, PBS. http://www.pbs.org/wgbh/nova/next/body/ebola-drug-halted/.
77. Warren TK,, Wells J,, Panchal RG,, Stuthman KS,, Garza NL,, Van Tongeren SA,, Dong L,, Retterer CJ,, Eaton BP,, Pegoraro G,, Honnold S,, Bantia S,, Kotian P,, Chen X,, Taubenheim BR,, Welch LS,, Minning DM,, Babu YS,, Sheridan WP,, Bavari S . 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508 : 402405.[PubMed] [CrossRef]
78. U.S. Securities and Exchange Commission . 2015. Biocryst Pharmaceuticals. 10-Q report. http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/gfpf10q_080715.htm.
79. ClinicalTrialsgov . 2014. A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of BCX4430. https://clinicaltrials.gov/ct2/show/NCT02319772.
80. U.S. Department of Health and Human Services . 2015. HHS contracts to develop new Ebola drug. http://www.hhs.gov/news/press/2015pres/03/20150331a.html.
81. Furuta Y,, Takahashi K,, Shiraki K,, Sakamoto K,, Smee DF,, Barnard DL,, Gowen BB,, Julander JG,, Morrey JD . 2009. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 82 : 95102.[PubMed] [CrossRef]
82. Morrey JD,, Taro BS,, Siddharthan V,, Wang H,, Smee DF,, Christensen AJ,, Furuta Y . 2008. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 80 : 377379.[PubMed] [CrossRef]
83. Julander JG,, Shafer K,, Smee DF,, Morrey JD,, Furuta Y . 2009. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 53 : 202209.[PubMed] [CrossRef]
84. Safronetz D,, Rosenke K,, Westover JB,, Martellaro C,, Okumura A,, Furuta Y,, Geisbert J,, Saturday G,, Komeno T,, Geisbert TW,, Feldmann H,, Gowen BB . 2015. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 5 : 14775. doi:10.1038/srep14775. [PubMed] [CrossRef]
85. Oestereich L,, Lüdtke A,, Wurr S,, Rieger T,, Muñoz-Fontela C,, Günther S . 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105 : 1721.[PubMed] [CrossRef]
86. Smither SJ,, Eastaugh LS,, Steward JA,, Nelson M,, Lenk RP,, Lever MS . 2014. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 104 : 153155.[PubMed] [CrossRef]
87. Jacobs M,, Aarons E,, Bhagani S,, Buchanan R,, Cropley I,, Hopkins S,, Lester R,, Martin D,, Marshall N,, Mepham S,, Warren S,, Rodger A . 2015. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis 15 : 13001304.[PubMed] [CrossRef]
88. Schibler M,, Vetter P,, Cherpillod P,, Petty TJ,, Cordey S,, Vieille G,, Yerly S,, Siegrist C-A,, Samii K,, Dayer J-A,, Docquier M,, Zdobnov EM,, Simpson AJH,, Rees PSC,, Sarria FB,, Gasche Y,, Chappuis F,, Iten A,, Pittet D,, Pugin J,, Kaiser L . 2015. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis 15 : 10341040.[CrossRef]
89. Petrosillo N,, Nicastri E,, Lanini S,, Capobianchi MR,, Di Caro A,, Antonini M,, Puro V,, Lauria FN,, Shindo N,, Magrini N,, Kobinger GP,, Ippolito G , INMI EBOV Team . 2015. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis 15 : 432. [PubMed] [CrossRef]
90. Wolf T,, Kann G,, Becker S,, Stephan C,, Brodt H-R,, de Leuw P,, Grünewald T,, Vogl T,, Kempf VAJ,, Keppler OT,, Zacharowski K . 2015. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385 : 14281435.[PubMed] [CrossRef]
91. ClinicalTrialsgov . 2015. Efficacy of favipiravir against ebola (JIKI). https://clinicaltrials.gov/ct2/show/NCT02329054?term=favipiravir&rank=5.
92. Sissoko D,, Anglaret X,, Malvy D,, Folkesson E,, M’lebing A,, Shepherd S,, Danel C,, Beavogui AH,, Gunther S,, Mentre F . 2015. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea, abstr 103-ALB. Abstr. Conf Retroviruses and Opportunistic Infections, Int Antiviral Soc, Seattle, WA. http://www.croiconference.org/sessions/favipiravir-patients-ebola-virus-disease-early-results-jiki-trial-guinea.
93. Thi EP,, Mire CE,, Lee ACH,, Geisbert JB,, Zhou JZ,, Agans KN,, Snead NM,, Deer DJ,, Barnard TR,, Fenton KA,, MacLachlan I,, Geisbert TW . 2015. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521 : 362365.[PubMed] [CrossRef]
94. Geisbert TW,, Hensley LE,, Kagan E,, Yu EZ,, Geisbert JB,, Daddario-DiCaprio K,, Fritz EA,, Jahrling PB,, McClintock K,, Phelps JR,, Lee ACH,, Judge A,, Jeffs LB,, MacLachlan I . 2006. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 193 : 16501657.[PubMed] [CrossRef]
95. Geisbert TW,, Lee AC,, Robbins M,, Geisbert JB,, Honko AN,, Sood V,, Johnson JC,, de Jong S,, Tavakoli I,, Judge A,, Hensley LE,, Maclachlan I . 2010. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375 : 18961905.[PubMed] [CrossRef]
96. Kroll D . 2014. Tekmira tempers FDA OK for Ebola drug access. http://www.forbes.com/sites/davidkroll/2014/09/22/tekmira-tempers-fda-ok-for-ebola-drug-access/.
97. Associated Press . 2015. Tekmira says Ebola drug unlikely to work in study. US News World Rep. http://www.usnews.com/news/business/articles/2015/06/19/tekmira-stops-adding-patients-in-african-study-of-ebola-drug.
98. ClinicalTrialsgov . 2015. Safety, tolerability and pharmacokinetic first in human (FIH) study for intravenous (IV) TKM-100802. https://clinicaltrials.gov/ct2/show/NCT02041715.
99. Warren T . 2015. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of Ebola virus disease (EVD) in infected non-human primates. Presented at ID Week 2015, San Diego, CA. https://idsa.confex.com/idsa/2015/webprogram/Paper54208.html.
100. Donnelly L . 2015. Ebola caused meningitis in nurse Pauline Cafferkey. The Telegraph. http://www.telegraph.co.uk/news/health/news/11945802/Ebola-caused-meningitis-in-nurse-Pauline-Cafferkey.html.
101. Lawson ND,, Stillman EA,, Whitt MA,, Rose JK . 1995. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92 : 44774481.[PubMed] [CrossRef]
102. Garbutt M,, Liebscher R,, Wahl-Jensen V,, Jones S,, Möller P,, Wagner R,, Volchkov V,, Klenk H-D,, Feldmann H,, Ströher U . 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 : 54585465.[PubMed] [CrossRef]
103. Jones SM,, Feldmann H,, Ströher U,, Geisbert JB,, Fernando L,, Grolla A,, Klenk HD,, Sullivan NJ,, Volchkov VE,, Fritz EA,, Daddario KM,, Hensley LE,, Jahrling PB,, Geisbert TW . 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 : 786790.[PubMed] [CrossRef]
104. Marzi A,, Robertson SJ,, Haddock E,, Feldmann F,, Hanley PW,, Scott DP,, Strong JE,, Kobinger G,, Best SM,, Feldmann H . 2015. EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 349 : 739742.[PubMed] [CrossRef]
105. Feldmann H,, Jones SM,, Daddario-DiCaprio KM,, Geisbert JB,, Ströher U,, Grolla A,, Bray M,, Fritz EA,, Fernando L,, Feldmann F,, Hensley LE,, Geisbert TW . Effective post-exposure treatment of Ebola infection. PLoS Pathog 3 : e2. doi:10.1371/journal.ppat.0030002. [PubMed] [CrossRef]
106. Lai L,, Davey R,, Beck A,, Xu Y,, Suffredini AF,, Palmore T,, Kabbani S,, Rogers S,, Kobinger G,, Alimonti J,, Link CJ Jr,, Rubinson L,, Ströher U,, Wolcott M,, Dorman W,, Uyeki TM,, Feldmann H,, Lane HC,, Mulligan MJ . 2015. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 313 : 12491255.[PubMed] [CrossRef]
107. Schnirring L . 2014. NewLink, Merck deal boosts prospects for Ebola vaccine. Univ Minn CIDRAP. http://www.cidrap.umn.edu/news-perspective/2014/11/newlink-merck-deal-boosts-prospects-ebola-vaccine.
108. Genetic Engineering and Biotechnology News . 2014. BARDA awards $30M toward NewLink-Merck Ebola vaccine candidate. http://www.genengnews.com/gen-news-highlights/barda-awards-30m-toward-newlink-merck-ebola-vaccine-candidate/81250726/.
109. Agnandji ST,, Huttner A,, Zinser ME,, Njuguna P,, Dahlke C,, Fernandes JF,, Yerly S,, Dayer J-A,, Kraehling V,, Kasonta R,, Adegnika AA,, Altfeld M,, Auderset F,, Bache EB,, Biedenkopf N,, Borregaard S,, Brosnahan JS,, Burrow R,, Combescure C,, Desmeules J,, Eickmann M,, Fehling SK,, Finckh A,, Goncalves AR,, Grobusch MP,, Hooper J,, Jambrecina S,, Kabwende AL,, Kaya G,, Kimani D,, Lell B,, Lemaître B,, Lohse AW,, Massinga-Loembe M,, Matthey A,, Mordmüller B,, Nolting A,, Ogwang C,, Ramharter M,, Schmidt-Chanasit J,, Schmiedel S,, Silvera P,, Stahl FR,, Staines HM,, Strecker T,, Stubbe HC,, Tsofa B,, Zaki Z,, Fast P,, Moorthy V,, Kaiser L,, Krishna S,, Stephan Becker S,, Kieny M-P,, Bejon P,, Kremsner PG,, Addo MM,, Siegrist C-A . 2015. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe: preliminary report. N Engl J Med. doi:10.1056/NEJMoa1502924. [CrossRef]
110. Pierson JF . 2015. Overview of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Study. Presentation to the Vaccines and Related Biological Products Advisory Committee, Silver Spring, MD. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM448001.pdf.
111. Helfand R . 2015. Overview of the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) Study. Presentation to the Vaccines and Related Biological Products Advisory Committee, Silver Spring, MD. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM448002.pdf.
112. Ebola ça Suffit Ring Vaccination Trial Consortium . 2015. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 351 : h3740. [PubMed]
113. Henao-Restrepo AM,, Longini IM,, Egger M,, Dean NE,, Edmunds WJ,, Camacho A,, Carroll MW,, Doumbia M,, Draguez B,, Duraffour S,, Enwere G,, Grais R,, Gunther S,, Hossmann S,, Kondé MK,, Kone S,, Kuisma E,, Levine MM,, Mandal S,, Norheim G,, Riveros X,, Soumah A,, Trelle S,, Vicari AS,, Watson CH,, Kéïta S,, Kieny MP,, Røttingen J-A . 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 : 857866.[PubMed] [CrossRef]
114. Krause PR . 2015. Interim results from a phase 3 Ebola vaccine study in Guinea. Lancet 386 : 831833.[PubMed] [CrossRef]
115. Sullivan NJ,, Sanchez A,, Rollin PE,, Yang ZY,, Nabel GJ . 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 : 605609.[PubMed] [CrossRef]
116. Sullivan NJ,, Geisbert TW,, Geisbert JB,, Xu L,, Yang ZY,, Roederer M,, Koup RA,, Jahrling PB,, Nabel GJ . 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 : 681684.[PubMed] [CrossRef]
117. Sullivan NJ,, Geisbert TW,, Geisbert JB,, Shedlock DJ,, Xu L,, Lamoreaux L,, Custers JHHV,, Popernack PM,, Yang Z-Y,, Pau MG,, Roederer M,, Koup RA,, Goudsmit J,, Jahrling PB,, Nabel GJ . 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3 : e177. doi:10.1371/journal.pmed.0030177. [CrossRef]
118. Sullivan NJ,, Hensley L,, Asiedu C,, Geisbert TW,, Stanley D,, Johnson J,, Honko A,, Olinger G,, Bailey M,, Geisbert JB,, Reimann KA,, Bao S,, Rao S,, Roederer M,, Jahrling PB,, Koup RA,, Nabel GJ . 2011. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17 : 11281131.[PubMed] [CrossRef]
119. Ledgerwood JE,, DeZure AD,, Stanley DA,, Novik L,, Enama ME,, Berkowitz NM,, Hu Z,, Joshi G,, Ploquin A,, Sitar S,, Gordon IJ,, Plummer SA,, Holman LA,, Hendel CS,, Yamshchikov G,, Roman F,, Nicosia A,, Colloca S,, Cortese R,, Bailer RT,, Schwartz RM,, Roederer M,, Mascola JR,, Koup RA,, Sullivan NJ,, Graham BS , the VRC 207 Study Team . 2014. Chimpanzee adenovirus vector Ebola vaccine: preliminary report. N Engl J Med 373 : 775776.[CrossRef]
120. Rampling T,, Ewer K,, Bowyer G,, Wright D,, Imoukhuede EB,, Payne R,, Hartnell F,, Gibani M,, Bliss C,, Minhinnick A,, Wilkie M,, Venkatraman N,, Poulton I,, Lella N,, Roberts R,, Sierra-Davidson K,, Krähling V,, Berrie E,, Roman F,, De Ryck I,, Nicosia A,, Sullivan NJ,, Stanley DA,, Ledgerwood JE,, Schwartz RM,, Siani L,, Colloca S,, Folgori A,, Di Marco S,, Cortese R,, Becker S,, Graham BS,, Koup RA,, Levine MM,, Moorthy V,, Pollard AJ,, Draper SJ,, Ballou WR,, Lawrie A,, Gilbert SC,, Hill AVS . 2015. A monovalent chimpanzee adenovirus Ebola vaccine: preliminary report. N Engl J Med. [Epub ahead of print.] doi:10.1056/NEJMoa1411627. [CrossRef]
121. Geisbert TW,, Bailey M,, Hensley L,, Asiedu C,, Geisbert J,, Stanley D,, Honko A,, Johnson J,, Mulangu S,, Pau MG,, Custers J,, Vellinga J,, Hendriks J,, Jahrling P,, Roederer M,, Goudsmit J,, Koup R,, Sullivan NJ . 2011. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol 85 : 42224233.[PubMed] [CrossRef]
122. Stanley DA,, Honko AN,, Asiedu C,, Trefry JC,, Lau-Kilby AW,, Johnson JC,, Hensley L,, Ammendola V,, Abbate A,, Grazioli F,, Foulds KE,, Cheng C,, Wang L,, Donaldson MM,, Colloca S,, Folgori A,, Roederer M,, Nabel GJ,, Mascola J,, Nicosia A,, Cortese R,, Koup RA,, Sullivan NJ . 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 20 : 11261129.[PubMed] [CrossRef]
123. Genetic Engineering and Biotechnology News . 2014. Janssen, Bavarian Nordic enter Ebola vaccine deal. GEN News. http://www.genengnews.com/gen-news-highlights/janssen-bavarian-nordic-enter-ebola-vaccine-deal/81250500/.
124. Mire CE,, Geisbert JB,, Agans KN,, Satterfield BA,, Versteeg KM,, Fritz EA,, Feldmann H,, Hensley LE,, Geisbert TW . 2014. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLoS One 9 : e94355. doi:10.1371/journal.pone.0094355. [PubMed] [CrossRef]
125. Grover N . 2015. Novavax starts Ebola vaccine trial in humans. Reuters. http://www.reuters.com/article/us-health-ebola-novavax-idUSKBN0LG1NX20150212.
126. World Health Organization . 2014. WHO consultation on potential Ebola therapies and vaccines. WHO, Geneva, Switzerland. http://www.who.int/csr/resources/publications/ebola/ebola-therapies/en/.
127. Cox E,, Borio L,, Temple R . 2014. Evaluating Ebola therapies: the case for RCTs. N Engl J Med 371 : 23502351.[PubMed] [CrossRef]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error